EA1242

Please Note:

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.

Available Sites

• Missouri Baptist Medical Center
• Missouri Baptist Sullivan Hospital
• Sainte Genevieve County Memorial Hospital
• Parkland Health Center - Farmington

Contact Person(s)

• Opal Potter 314-996-5865

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.